drugset
drugset / Trial / NCT05051553

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

NCT05051553 ↗

Phase 1 Completed 58 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability of fedratinib in healthy adult participants.

Timeline

Start
2021-09-21
Primary completion
2021-12-23
Completion
2022-04-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fedratinib Small molecule 200 mg Oral
Subject Fedratinib Small molecule 400 mg Oral

Indications

No indication recorded.